From the Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee.
J Natl Compr Canc Netw. 2017 Jun;15(6):835-840. doi: 10.6004/jnccn.2017.0102.
One in 5 patients who undergo surgical resection for clinically localized renal cell carcinoma (RCC) develop local and/or distant recurrences which, when detected early, may be amenable to salvage local and systemic therapies. When considering that approximately half of these recurrences will occur during the first 2 years, a clear rationale exists for optimizing surveillance strategies after surgery. Although there is a notable dearth of high-quality data on this subject, clinical principles can guide clinicians as they attempt to balance the burden of surveillance strategies with potential clinical benefit. The objective of this review is to summarize the evidence regarding optimal surveillance protocols after surgery for RCC. We provide an overview of the rationale supporting surveillance after surgery, a summary of the American Urological Association and NCCN guidelines, reasons against routine long-term surveillance, surveillance costs, and ancillary issues, such as the utility of bone scan, PET/CT scan, and surveillance after thermoablation.
五分之一的接受手术切除局限性肾细胞癌 (RCC) 的患者会出现局部和/或远处复发,如果早期发现,可能适合进行挽救性局部和全身治疗。考虑到这些复发中有近一半将在头 2 年内发生,因此术后优化监测策略具有明确的理由。尽管关于这个主题的高质量数据明显缺乏,但临床原则可以指导临床医生在试图平衡监测策略的负担与潜在的临床益处时。本篇综述的目的是总结手术后监测 RCC 的最佳方案的证据。我们提供了支持手术后监测的基本原理概述、美国泌尿外科学会和 NCCN 指南的总结、反对常规长期监测的理由、监测成本以及辅助问题(如骨扫描、PET/CT 扫描和热消融后的监测)。